Literature DB >> 18272557

Brain tumor imaging in clinical trials.

J W Henson1, S Ulmer, G J Harris.   

Abstract

SUMMARY: There are substantial challenges in the radiologic evaluation of tumor size during clinical trials, and it is important for neuroradiologists to have a firm understanding of these issues. This review will examine measurement approaches, response criteria, selection of lesions for measurement, technical imaging considerations, interval between tumor measurements and response confirmation, and validity of imaging as a measure of efficacy.

Entities:  

Mesh：

Year:  2008        PMID： 18272557      PMCID： PMC8118884          DOI： 10.3174/ajnr.A0963

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  19 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

3.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

4.  Response and progression in recurrent malignant glioma.

Authors:  K R Hess; E T Wong; K A Jaeckle; A P Kyritsis; V A Levin; M D Prados; W K Yung
Journal:  Neuro Oncol       Date:  1999-10       Impact factor: 12.300

Review 5.  Clinical trials in neuro-oncology.

Authors:  T Batchelor; K Stanley; J Andersen
Journal:  Curr Opin Neurol       Date:  2001-12       Impact factor: 5.710

6.  Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors.

Authors:  K E Warren; N Patronas; A A Aikin; P S Albert; F M Balis
Journal:  J Natl Cancer Inst       Date:  2001-09-19       Impact factor: 13.506

7.  Chemotherapy response criteria in malignant glioma.

Authors:  R Grant; B C Liang; J Slattery; H S Greenberg; L Junck
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

8.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

9.  Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

Authors:  Michael D Prados; Wendy Seiferheld; Howard M Sandler; Jan C Buckner; Theodore Phillips; Christopher Schultz; Raul Urtasun; Richard Davis; Philip Gutin; Terrence L Cascino; Harry S Greenberg; Walter J Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

10.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors:  J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal:  J Natl Cancer Inst       Date:  1998-10-07       Impact factor: 13.506
View more
  66 in total

1.  Can we improve accuracy and reliability of MRI interpretation in children with optic pathway glioma? Proposal for a reproducible imaging classification.

Authors:  Julien Lambron; Josué Rakotonjanahary; Didier Loisel; Eric Frampas; Emilie De Carli; Matthieu Delion; Xavier Rialland; Frédérique Toulgoat
Journal:  Neuroradiology       Date:  2015-10-30       Impact factor: 2.804

2.  A novel magnetic resonance imaging segmentation technique for determining diffuse intrinsic pontine glioma tumor volume.

Authors:  Ranjodh Singh; Zhiping Zhou; Jamie Tisnado; Sofia Haque; Kyung K Peck; Robert J Young; Apostolos John Tsiouris; Sunitha B Thakur; Mark M Souweidane
Journal:  J Neurosurg Pediatr       Date:  2016-07-08       Impact factor: 2.375

3.  Tumor Response Assessment in Diffuse Intrinsic Pontine Glioma: Comparison of Semiautomated Volumetric, Semiautomated Linear, and Manual Linear Tumor Measurement Strategies.

Authors:  L A Gilligan; M D DeWire-Schottmiller; M Fouladi; P DeBlank; J L Leach
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-30       Impact factor: 3.825

Review 4.  Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Authors:  Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-02-24       Impact factor: 4.130

Review 5.  Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases.

Authors:  M G Hart; R Grant; M Walker; H Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

6.  Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases.

Authors:  Yalei Zhang; Haihong Yang; Xinyun Yang; Qiuhua Deng; Meilin Zhao; Xin Xu; Jianxing He
Journal:  Mol Clin Oncol       Date:  2014-02-11

Review 7.  Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.

Authors:  John H Rossmeisl; Paulo A Garcia; Gregory B Daniel; John Daniel Bourland; Waldemar Debinski; Nikolaos Dervisis; Shawna Klahn
Journal:  Vet Radiol Ultrasound       Date:  2013-11-13       Impact factor: 1.363

8.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

9.  Impact of perfusion map analysis on early survival prediction accuracy in glioma patients.

Authors:  Benjamin Lemasson; Thomas L Chenevert; Theodore S Lawrence; Christina Tsien; Pia C Sundgren; Charles R Meyer; Larry Junck; Jennifer Boes; Stefanie Galbán; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross; Craig J Galbán
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

10.  GLISTR: glioma image segmentation and registration.

Authors:  Ali Gooya; Kilian M Pohl; Michel Bilello; Luigi Cirillo; George Biros; Elias R Melhem; Christos Davatzikos
Journal:  IEEE Trans Med Imaging       Date:  2012-08-13       Impact factor: 10.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.